Skip to content
DataLookout
Menu

NCT04387916

A Study of KC1036 in Patients with Advanced Solid Tumors

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Jul 31, 2023 to Oct 31, 2025
    • Study completion date: Jul 31, 2024 to Dec 31, 2025
    • Site contacts updated at 3 of 3 sites
    v5
  3. Notable Primary completion date: Jul 31, 2022 to Jul 31, 2023
    • Study completion date: Jul 31, 2023 to Jul 31, 2024
    v4
  4. Notable Enrollment target: 108 to 207
    • Eligibility criteria shortened, about 30 words
    • Study sites: 1 to 3
    • Secondary endpoints: 8 to 9
    v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 31, 2020 to Sep 4, 2020
    • Site details revised
    • Study title shortened, about 2 words
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD)
Timeframe: First 4 weeks after initial administration of KC1036
Adverse events (AEs)
Timeframe: From enrollment up to 30 days after last dose

Secondary (9)

Pharmacokinetics (PK) profile: Cmax
Pharmacokinetics (PK) profile: Tmax
Pharmacokinetics (PK) profile: T1/2
Pharmacokinetics (PK) profile: AUC0-t and AUC0-∞
Objective Response Rate (ORR)
Show 4 moreShow less
Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Overall Survival (OS)

Arms and interventions

KC1036Experimental

Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.

Drugs: KC1036

Sites

3 sites in 1 country